Flinn, I. W., Jacobson, C. A., Nastoupil, L. J., Morschhauser, F., Davies, A., Buske, C., Corradini, P., Lopez‐Guillermo, A., Reshef, R., Parameswaran, V., Sehgal, A., Tees, M., Lui, C., Xue, W., Beygi, S., Grechko, N., Bolsue, P., Giovanetti, A., To, C., & Nahas, M. (2023). ZUMA‐22: A PHASE 3, RANDOMIZED CONTROLLED STUDY OF AXICABTAGENE CILOLEUCEL (AXI‐CEL) VS STANDARD‐OF‐CARE THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA. Hematological Oncology, 41(S2), 853–855. Portico. https://doi.org/10.1002/hon.3166_ot31
Subjects:
Chimeric Antigen Receptor T Cell Therapy
(OpenAlex Topic)
Lymphoid Neoplasms
(OpenAlex Topic)
Publication Type:
Article
Unique ID:
10.1002/hon.3166_ot31
Journal:
Publication Date:
Data Source:
OpenAlex
Source Link: